Locust Wood Capital Advisers’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-142,053
| Closed | -$49.8M | – | 36 |
|
|
2025
Q4 | $49.8M | Sell |
142,053
-1,118
| -0.8% | -$378K | 1.2% | 30 |
|
|
2025
Q3 | $46.3M | Sell |
143,171
-182,654
| -56% | -$56.8M | 1.15% | 29 |
|
|
2025
Q2 | $127M | Buy |
325,825
+654
| +0.2% | +$263K | 3.38% | 11 |
|
|
2025
Q1 | $141M | Buy |
325,171
+68,128
| +27% | +$27.3M | 4.48% | 7 |
|
|
2024
Q4 | $94.8M | Buy |
257,043
+18,598
| +8% | +$7.78M | 3.27% | 14 |
|
|
2024
Q3 | $124M | Sell |
238,445
-60,961
| -20% | -$32.6M | 4.14% | 6 |
|
|
2024
Q2 | $162M | Buy |
299,406
+9,592
| +3% | +$5.07M | 5.81% | 3 |
|
|
2024
Q1 | $150M | Buy |
289,814
+3,745
| +1% | +$1.86M | 5.38% | 3 |
|
|
2023
Q4 | $135M | Buy |
286,069
+108,814
| +61% | +$50.3M | 5.12% | 4 |
|
|
2023
Q3 | $77.2M | Sell |
177,255
-55,680
| -24% | -$25.3M | 3.28% | 13 |
|
|
2023
Q2 | $103M | Buy |
232,935
+23,343
| +11% | +$10.8M | 4.81% | 3 |
|
|
2023
Q1 | $96.4M | Buy |
209,592
+51,367
| +32% | +$24.4M | 5.64% | 2 |
|
|
2022
Q4 | $81.2M | Buy |
158,225
+3,270
| +2% | +$1.66M | 4.55% | 4 |
|
|
2022
Q3 | $70.4M | Buy |
154,955
+14,617
| +10% | +$6.99M | 4.86% | 2 |
|
|
2022
Q2 | $67.7M | Sell |
140,338
-64,272
| -31% | -$31.8M | 4.19% | 6 |
|
|
2022
Q1 | $101M | Buy |
204,610
+42,062
| +26% | +$19.2M | 5.51% | 3 |
|
|
2021
Q4 | $75.3M | Buy |
162,548
+38,152
| +31% | +$16.1M | 3.77% | 4 |
|
|
2021
Q3 | $46.4M | Buy |
124,396
+2,187
| +2% | +$831K | 2.52% | 18 |
|
|
2021
Q2 | $46.7M | Buy |
122,209
+4,822
| +4% | +$1.84M | 2.68% | 18 |
|
|
2021
Q1 | $42.1M | Buy |
117,387
+5,339
| +5% | +$1.72M | 2.48% | 20 |
|
|
2020
Q4 | $36M | Buy |
112,048
+17,060
| +18% | +$5.24M | 2.05% | 18 |
|
|
2020
Q3 | $25.5M | Sell |
94,988
-77,915
| -45% | -$21M | 1.65% | 25 |
|
|
2020
Q2 | $45.5M | Buy |
172,903
+80,000
| +86% | +$21.3M | 2.82% | 10 |
|
|
2020
Q1 | $21.1M | Sell |
92,903
-80,872
| -47% | -$22M | 1.78% | 24 |
|
|
2019
Q4 | $52.5M | Buy |
173,775
+14,055
| +9% | +$3.87M | 3.89% | 6 |
|
|
2019
Q3 | $38.3M | Sell |
159,720
-23,614
| -13% | -$6.47M | 3.24% | 12 |
|
|
2019
Q2 | $51.7M | Sell |
183,334
-6,240
| -3% | -$1.7M | 3.82% | 8 |
|
|
2019
Q1 | $54.4M | Buy |
189,574
+72,814
| +62% | +$21.1M | 4.25% | 6 |
|
|
2018
Q4 | $30.7M | Buy |
116,760
+51,325
| +78% | +$14.1M | 2.36% | 15 |
|
|
2018
Q3 | $17.9M | Buy |
+65,435
| New | +$17M | 1.24% | 30 |
|
Other funds holding ELV
Locust Wood Capital Advisers's ELV Position: Q1 2026 in Review
Locust Wood Capital Advisers sold out of Elevance Health (ELV) in Q1 2026, closing a stake of 142,053 shares — an estimated $49.8M sold.
Locust Wood Capital Advisers first reported a position in ELV in Q3 2018 and held it in 30 quarters. The position peaked at $162M in Q2 2024. 1,468 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Locust Wood Capital Advisers reported no remaining Elevance Health position as of Q1 2026 after selling out during the quarter.
- Locust Wood Capital Advisers sold 142,053 Elevance Health shares in Q1 2026, an estimated $49.8M.
- Locust Wood Capital Advisers first reported a position in Elevance Health in Q3 2018 and held it in 30 quarters.
- Locust Wood Capital Advisers's Elevance Health position peaked at $162M in Q2 2024.
- 1,468 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Locust Wood Capital Advisers's 13F filing for Q1 2026, filed 11 May 2026.